BACKGROUND Previous studies have indicated an association between obesity and poor survival in several tumour types, including ovarian cancer. We sought to test the hypothesis that obesity reduces survival in a large, well-characterised and relatively homogeneous cohort of ovarian cancer patients. PATIENTS AND METHODS The relationship between body mass index (BMI) and overall survival (OS) an...

The overall survival (OS) of patients with ovarian cancer is poor while epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer. The aim of the present study was to evaluate the clinico-pathologic characteristics, especially the prognostic factors, for patients with epithelial ovarian cancer (EOC) in Taiwan. Information about newly diagnosed patients with EOC from 2009 to 2012 was...

Ovarian cancer is the most lethal gynecological malignancy, for which platinum- and taxane-based chemotherapy plays a major role. Chemoresistance of ovarian cancer poses a major obstacle to the successful management of this devastating disease; however, effective measures to overcome platinum and taxane resistance are yet to be established. In the present study, while investigating the mechanis...

Treatment with T-DM1, either alone or in combination with pertuzumab (Perjeta, Genentech), produces noninferior progression-free survival (PFS) compared with the standard first-line treatment for HER2-positive metastatic breast cancer (trastuzumab and a taxane), according to primary results from the phase 3 MARIANNE study. The addition of pertuzumab to T-DM1 did not improve PFS. Although T-DM1 ...

PURPOSE Combination therapy consisting of an oral taxane, BMS-275183, and the anti-epidermal growth factor receptor monoclonal antibody, cetuximab, was assessed for enhanced therapeutic benefit in preclinical tumor models. EXPERIMENTAL DESIGN Mice bearing human tumor xenografts, either L2987 lung or GEO colon carcinoma, were administered the aforementioned treatments singly or in combination ...

BACKGROUND We determined the objective response rates produced by pegylated liposomal doxorubicin (PLD) plus carboplatin with/without trastuzumab (Herceptin). PATIENTS AND METHODS Patients with measurable disease were stratified by taxane treatment history and human epidermal growth factor receptor-2 status. TREATMENT PLD 30 mg/m(2) followed by carboplatin, day 1 of each 28-day cycle; human...

The taxane-based therapy provides survival benefit in patients with metastatic prostate cancer; however, the average is less than 20 months due to partial taxane-related chemoresistance. Innovative strategies are needed overcome chemoresistance for improved patient survival. In this project, paclitaxel-resistance was developed on androgen-independent PC3 and androgen-dependent 22Rv1 LNCaP human...

introduction: breast cancers are divided into at least 4 sub types on the basis of gene expression profiles and expression of receptors as measured by ihc (immunohistochemical). triple negative breast cancer (tnbc) is more chemosensitive yet, it is much harder to detect than other sub types. at present lack of highly effective therapeutic targets for tnbc, leaves standard chemotherapy, as the o...